AquaBounty Technologies, Inc., a biotechnology company, develops and markets products to enhance productivity in aquaculture. It offers AquAdvantage Salmon, a genetically modified Atlantic salmon for human consumption. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was founded in 1991 and is headquartered in Maynard, Massachusetts. AquaBounty Technologies, Inc. is a subsidiary of Intrexon Corporation.
Industry, Sector and Symbol
Industry Fishing, hunting & trapping
Sub-IndustryN/A
SectorMedical
Phone978-648-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.28 million
Profitability
Miscellaneous
Employees37
OptionableNot Optionable
Aquabounty Technologies (NASDAQ:AQB) Frequently Asked Questions
What is Aquabounty Technologies' stock symbol?
Aquabounty Technologies trades on the NASDAQ under the ticker symbol "AQB."
How were Aquabounty Technologies' earnings last quarter?
Aquabounty Technologies Inc (NASDAQ:AQB) posted its quarterly earnings results on Friday, November, 2nd. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.14 million. View Aquabounty Technologies' Earnings History.
When is Aquabounty Technologies' next earnings date?
What price target have analysts set for AQB?
1 brokers have issued 12-month price targets for Aquabounty Technologies' stock. Their predictions range from $4.00 to $4.00. On average, they expect Aquabounty Technologies' share price to reach $4.00 in the next year. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Price Targets for Aquabounty Technologies.
What is the consensus analysts' recommendation for Aquabounty Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquabounty Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquabounty Technologies.
What are Wall Street analysts saying about Aquabounty Technologies stock?
Here are some recent quotes from research analysts about Aquabounty Technologies stock:
- 1. According to Zacks Investment Research, "AquaBounty Technologies, Inc. is a biotechnology company. It focused on enhancing productivity in aquaculture. The company operates primarily in Maynard, Massachusetts and Fortune, Prince Edward Island. AquaBounty Technologies, Inc. is based in Maynard, United States. " (1/15/2019)
- 2. HC Wainwright analysts commented, "We are initiating coverage of Buy rating and setting a conservative $3.75 price target on what we see as the leading accelerating technology in creating and growing Atlantic salmon, arguably one of if not the healthiest protein choices as a key original source for the richest long-chain omega-3 fatty acids, EPA (eicosapentaenoic) and DHA (docosahexaenoic). Atlantic salmon has experienced moderately increasing consumption worldwide that has driven the creation of 3.2M metric ton (MT) global farmed Atlantic salmon production—roughly a $30B market—that represents a fraction of the approximate $177B global aquaculture market. Over the past eight years, U.S. imports of Atlantic salmon, estimated in the 300,000MT range—or $2.8B at wholesale—have escalated at rates above global Atlantic salmon production, signaling future domestic price increases." (6/28/2018)
Has Aquabounty Technologies been receiving favorable news coverage?
News headlines about AQB stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aquabounty Technologies earned a news sentiment score of 3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Aquabounty Technologies' key competitors?
Some companies that are related to Aquabounty Technologies include Fennec Pharmaceuticals (FENC), Erytech Pharma (ERYP), AgeX Therapeutics (AGE), Surface Oncology (SURF), Proteostasis Therapeutics (PTI), BioTime (BTX), BioTime (BTX), Menlo Therapeutics (MNLO), Adamis Pharmaceuticals (ADMP), BELLUS Health (BLUSF), Axovant Sciences (AXON), Millendo Therapeutics (MLND), Allena Pharmaceuticals (ALNA), Imprimis Pharmaceuticals (IMMY) and Harrow Health (HROW).
Who are Aquabounty Technologies' key executives?
Aquabounty Technologies' management team includes the folowing people:
- Mr. David A. Frank, CFO & Treasurer (Age 59)
- Dr. Ronald L. Stotish, Exec. Director (Age 70)
- Mr. Alejandro Rojas, Chief Operating Officer of Aquabounty Farms (Age 57)
- Ms. Sylvia Wulf, CEO, Pres & Director (Age 61)
- Mr. Christopher H. Martin, Gen. Counsel & Company Sec. (Age 53)
Who are Aquabounty Technologies' major shareholders?
Which major investors are buying Aquabounty Technologies stock?
How do I buy shares of Aquabounty Technologies?
Shares of AQB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aquabounty Technologies' stock price today?
One share of AQB stock can currently be purchased for approximately $2.50.
How big of a company is Aquabounty Technologies?
Aquabounty Technologies has a market capitalization of $37.75 million and generates $53.28 million in revenue each year. The company earns $-9,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Aquabounty Technologies employs 37 workers across the globe.
What is Aquabounty Technologies' official website?
How can I contact Aquabounty Technologies?
Aquabounty Technologies' mailing address is 2 MILL & MAIN PLACE SUITE 395, MAYNARD MA, 01754. The company can be reached via phone at 978-648-6000 or via email at [email protected]
MarketBeat Community Rating for Aquabounty Technologies (NASDAQ AQB)
MarketBeat's community ratings are surveys of what our community members think about Aquabounty Technologies and other stocks. Vote "Outperform" if you believe AQB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQB will underperform the S&P 500 over the long term. You may vote once every thirty days.
